Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
Marker Therapeutics Inc MRKR
$1.15
▼ -3.36%
($-0.04)
Open
$1.22
Prev Close
$1.19
Day Range
$1.15 – $1.22
52W Range
$0.84 – $2.46
Market Cap
$19.17M
Beta
1.60
EPS (TTM)
$-0.90
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-11-08 |
| Shares Out. | 16,670,000 |
| Website | markertherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 5 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.8M |
| Free Cash Flow | -$9.8M |
| Total Assets | $14.6M |
| Total Liabilities | $2.4M |
| Equity | $12.2M |
About Marker Therapeutics Inc
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Marker Therapeutics Inc is a publicly traded company under the ticker symbol MRKR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)